溴化(4-氟苯甲基)三苯基磷 | 51044-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 溴化(4-氟苯甲基)三苯基磷
• 中文别名: (4-氟苄基)三苯基溴化膦
• 英文名称: (4-fluorobenzyl)(triphenyl)phosphonium bromide
• 英文别名: p-fluorobenzyl-triphenylphosphonium bromide；(4-Fluorobenzyl)triphenylphosphonium bromide；(4-fluorophenyl)methyl-triphenylphosphanium;bromide
• CAS: 51044-11-2
• 化学式: Br*C₂₅H₂₁FP
• 分子量: 451.318
• InChiKey: DWIYANXFWXPJQY-UHFFFAOYSA-M

物化性质

• 熔点：
  280-282 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  应存放在室温、密封、干燥且惰性气体保护的环境中。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : (4-FLUOROBENZYL)TRIPHENYLPHOSPHONIUM
BROMIDE
CAS-No. : 51044-11-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C25H21BrFP
Molecular Weight : 451,32 g/mol
Component Concentration
(4-FLUOROBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE
CAS-No. 51044-11-2 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Oxides of phosphorus, Hydrogen bromide gas, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Inhalation: no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Specific target organ toxicity - single exposure
May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  溴化(4-氟苯甲基)三苯基磷 在 bis(N,N-dimethylformamide)dichlorodioxomolybdenum(VI) 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三苯基膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 20.0h， 生成 6-fluoro-2-(4-fluorophenyl)-1H-indole
  参考文献：
  名称：

  强大的芳香​​化酶抑制剂及其抑制作用的分子机理

  摘要：

  雌激素是激素依赖性乳腺癌的维持和发展的重要因素。众所周知，芳香酶介导雌激素的产生。因此，用化学分子抑制芳香酶被认为是雌激素受体阳性（ER +）乳腺癌的有效治疗方法。在这项工作中，我们设计和合成了一系列新型的非甾体分子，它们包含2-苯基吲哚骨架和咪唑或1,2,4-三唑部分，以增强它们与芳香酶的结合能力。在这些分子中，实验证实了一种名为8o的化合物对芳香化酶具有最高的抑制活性。进一步的细胞活性分析证明了化合物8o具有低细胞毒性，是开发新型芳香化酶抑制剂的有希望的先导。进行分子建模和模拟技术以鉴定来曲唑和8o与芳香化酶的结合模式。两种化合物-芳香化酶复合物的能量分析表明，与来曲唑相比，8o与芳香酶的结合能低（强结合亲和力），这与实验结果一致。综上所述，实验方法和计算方法的组合有助于我们理解抑制作用的分子机制，并发现针对芳香化酶的更有效的非甾体类AI，从而为激素依赖性乳腺癌开辟了新的治疗策略。

  DOI：

  10.1016/j.ejmech.2017.11.057
• 作为产物：
  描述：

  对氟甲苯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 甲苯 为溶剂， 反应 12.0h， 生成 溴化(4-氟苯甲基)三苯基磷
  参考文献：
  名称：

  苯并[c]菲的高效氟促进分子内缩合：直接合成富勒烯的新前景

  摘要：

  已经测试了各种官能团作为苯并 [c] 菲在快速真空热解条件下分子内缩合的替代促进剂。发现甲基和氟官能化是有前途的方法。在氟化苯并[c]菲的环化中观察到了出乎意料的高选择性。讨论了缩合反应的机理和氟作为促进富勒烯合理合成的促进剂的优势。 (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejoc.200900976

文献信息

• Substituted dienes prepared from betulinic acid – Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters
  作者：Jan Pokorný、Denisa Olejníková、Ivo Frydrych、Barbora Lišková、Soňa Gurská、Sandra Benická、Jan Šarek、Jana Kotulová、Marián Hajdúch、Petr Džubák、Milan Urban

  DOI：10.1016/j.ejmech.2021.113706

  日期：2021.11

  synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle

  通过将桦木酸氧化为 30-氧代桦木酸，然后进行 Wittig 反应，合成了一组新的取代二烯。在八种癌细胞系和两种非癌成纤维细胞中体外测试了所有化合物的细胞毒性。几乎所有的二烯都比桦木酸更具细胞毒性。化合物4.22、4.30、4.33、4.39的IC 50低于5 μmol / L ；选择4.22和4.39进行作用机制研究。细胞周期分析显示在 5 × IC 50时凋亡细胞数量增加浓度，其中可以预期导致细胞死亡的不可逆变化的激活。既4.22和4.39导致细胞在用DNA / RNA合成的部分抑制的G0 / G1期的累积为1×IC 50，并在5几乎完全抑制×IC 50。有趣的是，化合物4.39 在 5 × IC 50导致细胞在 S 期积累。较高浓度的受试药物可能比较低浓度抑制更多的脱靶。破坏细胞代谢的机制可以诱导细胞在 S 期的积累。化合物4.22和4.39 均在癌细胞中引发选择性凋亡通过内在途径，
• Synthesis of 2-phenylnaphthalenes from styryl-2-methoxybenzenes
  作者：Ramesh Mudududdla、Rohit Sharma、Sheenu Abbat、Prasad V. Bharatam、Ram A. Vishwakarma、Sandip B. Bharate

  DOI：10.1039/c4cc05151c

  日期：——

  A new simple and efficient method for the synthesis of 2-phenylnaphthalenes from electron-rich 1-styryl-2-methoxybenzenes has been described. The reaction proceeds via TFA catalyzed C-C bond cleavage followed by intermolecular [4+2]-Diels-Alder cycloaddition of an in situ formed styrenyl trifluoroacetate intermediate. The quantum chemical calculations identified the transition state for the cycloaddition

  已经描述了一种从富电子的1-苯乙烯基-2-甲氧基苯合成2-苯基萘的简单而有效的新方法。该反应通过TFA催化的CC键裂解进行，然后原位形成的苯乙烯基三氟乙酸酯中间体的分子间[4 + 2] -Diels-Alder环加成反应。量子化学计算确定了环加成反应的过渡态，并有助于追踪反应机理。该方法已被有效地用于合成菲骨架和基于萘的强效选择性ER-β激动剂。
• Gold(I)-Catalyzed Enantioselective Synthesis of Tetrahydrocarbazoles through Dearomative [4+2] Cycloadditions of 3/2-Substituted 2/3-Vinylindoles
  作者：Valentina Pirovano、Micol Borri、Giorgio Abbiati、Silvia Rizzato、Elisabetta Rossi

  DOI：10.1002/adsc.201700280

  日期：2017.6.6

  The gold‐catalyzed synthesis of tetrahydrocarbazoles through dearomative [4+2] cycloaddition reactions of 3/2‐substituted 2/3‐vinylindoles with allenamides is reported. In particular, we optimized the enantioselective variant of these cycloadditions. Using allenamides as dienophiles 3‐substituted 2‐vinylindoles gave the corresponding carbazoles with high chemo‐, regio‐ and enantioselectivity. Good

  据报道，金催化的是3 / 2-取代的2 / 3-乙烯基吲哚与烯丙基酰胺的脱芳香性[4 + 2]环加成反应，合成四氢咔唑。特别是，我们优化了这些环加成的对映选择性变体。使用烯丙酰胺作为亲二烯体，可通过3-取代的2-乙烯基吲哚得到相应的咔唑，具有较高的化学，区域和对映体选择性。也获得与2-甲基-3- vinylindoles良好的结果，即使（的混合物Ž）和（ê）异构体在高分离ER和在良好的总收率。
• Synthesis and Biological Evaluation of Direct Thrombin Inhibitors Bearing 4-(Piperidin-1-yl)pyridine at the P1 Position with Potent Anticoagulant Activity
  作者：Modesto de Candia、Filomena Fiorella、Gianfranco Lopopolo、Andrea Carotti、Maria Rosaria Romano、Marcello Diego Lograno、Sophie Martel、Pierre-Alain Carrupt、Benny D. Belviso、Rocco Caliandro、Cosimo Altomare

  DOI：10.1021/jm401169a

  日期：2013.11.14

  (fIIa) and factor Xa (fXa) inhibition activities, anti-fIIa activity and artificial membrane permeability were considerably improved by optimizing the basic P1 and the X-substituted phenyl P4 binding moieties. Structure–activity relationship studies, usefully complemented with molecular modeling results, led us to identify compound 13b, which showed excellent fIIa inhibition (Ki = 6 nM), weak anti-Xa

  描述了一种新型的非肽类直接凝血酶抑制剂的设计和合成，该抑制剂建立在1-（吡啶-4-基）哌啶-4-羧酰胺的结构上。从显示弱的凝血酶（fIIa）和Xa因子（fXa）抑制活性的强碱性1- ami基哌啶衍生物（6）开始，通过优化碱性P1和X-取代的苯基P4可显着提高抗fIIa活性和人工膜通透性结合部分。结构-活性关系研究以及有用的分子建模结果使我们得以鉴定出化合物13b，该化合物表现出出色的fIIa抑制作用（K i = 6 nM），抗Xa活性弱（K i= 5.64μM），并且对其他丝氨酸蛋白酶（例如胰蛋白酶）具有显着的选择性。化合物13b在低微摩尔范围内显示出体外抗凝活性，并具有显着的膜通透性。在小鼠中（离体），13b在口服给药（100 mg·kg –1）后2 h表现出抗凝作用，与对照组相比，活化的部分凝血活酶时间（aPTT）延长了43％（P <0.05）。
• [EN] 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES<br/>[FR] 3-AMINO-1,5,6,7-TÉTRAHYDRO-4H-INDOL-4-ONES
  申请人：BAYER PHARMA AG

  公开号：WO2016202755A1

  公开（公告）日：2016-12-22

  Compounds of formula (I) as described hereinprocesses for their production and their use as anti-cancer agents.

  本文描述的式(I)化合物，其生产方法及其作为抗癌药物的用途。